Skip to main content
Fig. 2 | Lipids in Health and Disease

Fig. 2

From: Efficacy and safety of orlistat in male patients with overweight/obesity and hyperuricemia: results of a randomized, double-blind, placebo-controlled trial

Fig. 2

Percentage of patients who experienced gout flares in both groups. (A) Cumulative incidence of the first gout flare after initiation of treatment with orlistat or placebo in total participants. (B) Cumulative incidence of the first recurrent gout flare after initiation of treatment with orlistat or placebo in participants with gout. (C) Proportion of patients with gout flares per month among all participants. (D) Proportion of patients with recurrent gout flare per month in participants with gout

Back to article page

Lipids in Health and Disease

ISSN: 1476-511X